HOOKIPA BIOTECH GmbH

HOOKIPA BIOTECH GmbH is developing a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology.

The Vaxwave® technology is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer.

The company has raised a total of € 27 million in equity finance from internationally renowned venture capital investors.